High-yield overview

Open or arthroscopic removal of diseased synovium | localised vs diffuse disease dictates approach | intermediate

Surgical Imaging

Imaging Gallery

Open knee synovectomy field showing hypertrophic reddish-brown synovium in PVNS — Open knee synovectomy: surgical field with retractors exposing hypertrophic reddish-brown synovium in diffuse PVNS, with diseased tissue being excised.Credit: Jabalameli M et al. via Open-i NIH (PMC) (CC BY PMC Open Access)

Arthroscopic view of hypertrophic villous synovial proliferation in knee PVNS — Arthroscopic view of dense hypertrophic synovial fronds filling the knee joint, consistent with diffuse pigmented villonodular synovitis — the target tissue for arthroscopic synovectomy.Credit: Mohanlal P et al. via Open-i NIH (PMC) (CC BY PMC Open Access)

Six-panel PVNS case: radiographs, coronal MRI and histopathology of right knee — PVNS workup — six panels: (A, B) AP and lateral radiographs showing soft-tissue swelling; (C, D) coronal MRI demonstrating extensive synovial disease with low-signal areas from haemosiderin; (E, F) histopathology showing villous proliferation with haemosiderin-laden macrophages.Credit: Xie GP et al. via Open-i NIH (PMC) (CC BY PMC Open Access)

Intraoperative before and after synovectomy showing diffuse synovial papillae and excised specimen — Before (a) and after (b) synovectomy: panel (a) shows intraoperative diffuse papillae and yellowish-brown nodules of proliferating villonodular synovium around the prosthesis; panel (b) shows the excised gross specimen of lobulated synovial tissue.Credit: Tosun HB et al. via Open-i NIH (PMC) (CC BY PMC Open Access)

Excised PVNS synovectomy specimen — reddish-brown cystic-nodular mass with scalpel for scale — Excised synovectomy specimen for popliteal PVNS: reddish-brown cystic-nodular mass on surgical drape with a scalpel for scale, illustrating the extent of tissue removed.Credit: Gokhale N et al. via Open-i NIH (PMC) (CC BY PMC Open Access)

Critical Danger Structures

Danger 1: Popliteal Neurovascular Bundle

Popliteal artery, vein and tibial nerve. Location: Directly posterior to the posterior capsule, closest to the joint with the knee extended. Protection: Work with the knee flexed 70-90 degrees to allow the bundle to fall posteriorly, stay on the capsule, use a posterior cannula/retractor and never push instruments blindly through the posterior capsule. Catastrophic if breached during posterior synovectomy.

Danger 2: Common Peroneal Nerve

Common peroneal (fibular) nerve. Location: Postero-lateral, passing behind the biceps femoral tendon and around the fibular neck. Protection: During posterolateral portal placement or an open posterolateral approach, identify and protect the nerve behind biceps femoris; avoid aggressive lateral retraction. Injury causes foot drop.

Danger 3: Saphenous Nerve / Infrapatellar Branch

Saphenous nerve and its infrapatellar branch. Location: Medial side, crossing the anteromedial knee; the infrapatellar branch crosses transverse incisions. Protection: Use longitudinal medial incisions where possible, place the posteromedial portal carefully, retract with skin hooks. Injury causes a painful neuroma and medial/anterior numbness.

Danger 4: Incomplete Synovectomy / Recurrence

Residual diseased synovium - especially posterior compartment, gutters and intercondylar notch. Recurrence of diffuse PVNS reaches 8-46% and correlates with incomplete clearance. Protection: Systematically address all compartments, use posterior portals or a combined open posterior approach, and consider adjuvant radiotherapy for diffuse disease.

Danger 5: Arthrofibrosis / Stiffness

Post-operative arthrofibrosis and loss of motion. Location: Whole joint, worse after extensive open synovectomy and prolonged immobilisation. Protection: Meticulous haemostasis, early continuous passive motion and active range of motion, adequate analgesia, and avoiding unnecessarily prolonged splinting. Stiffness is the commonest functional complication.

Mnemonic

PAIRPAIR - Indications for Knee Synovectomy

Mnemonic

CLEARCLEAR - Principles of Complete Synovectomy

Primary Indications

Inflammatory / Rheumatoid Synovitis

Persistent boggy synovitis despite optimised medical therapy (DMARDs, biologics) for at least 6 months
Recurrent effusions and pain with preserved articular cartilage (best results in early, pre-erosive disease)
Aim is symptom control and slowing of joint destruction, not cure - benefit tends to diminish over years
Less commonly performed now in the biologic era, but still relevant when synovitis is monoarticular and drug-refractory

Pigmented Villonodular Synovitis (PVNS) / Diffuse-type Tenosynovial Giant Cell Tumour

Localised (nodular) PVNS: focal intra-articular nodule, often pedunculated - treated by local excision (frequently arthroscopic) with low recurrence
Diffuse PVNS: carpets the synovium, frequently involves the posterior compartment - requires total synovectomy and has a much higher recurrence rate
The knee is the most commonly affected joint (around 80% of PVNS cases)
Recurrence after surgery for diffuse disease ranges widely (reported 8-46%), driven by incomplete excision

Synovial Chondromatosis

Metaplastic cartilaginous/osteocartilaginous loose body formation within the synovium (Milgram phases)
Indication: mechanical symptoms (locking, catching), pain, effusion from loose bodies
Treatment = synovectomy plus removal of all loose bodies; recurrence relates to active synovial metaplasia

Haemophilic Arthropathy

Recurrent haemarthrosis causing chronic haemophilic synovitis that perpetuates a vicious bleed-synovitis-bleed cycle
Indicated when bleeds persist despite optimised factor prophylaxis (and after failure of radiosynovectomy in many algorithms)
Goal: reduce frequency of bleeds and slow cartilage destruction; performed earlier in the cascade than arthroplasty

Septic Arthritis (Adjunct)

Synovectomy/debridement as part of arthroscopic or open washout for established or relapsing septic arthritis
Removes infected, proliferative synovium and biofilm-laden tissue; combined with copious lavage and antibiotics

Contraindications

Active skin infection over portal/incision sites (unless the procedure is for sepsis)
End-stage arthritis where arthroplasty is more appropriate than synovectomy
Uncontrolled coagulopathy / inadequate factor cover in haemophilia
Medical comorbidity precluding anaesthesia

Open versus Arthroscopic Synovectomy

Arthroscopic

Faster recovery, less pain, lower wound morbidity, earlier return of motion and lower stiffness rates
Technically demanding; complete clearance of the posterior compartment requires posteromedial and posterolateral portals and considerable skill
Best suited to localised disease and diffuse disease confined to accessible compartments

Open

Allows more thorough clearance, especially for diffuse disease, large loose-body burden, or posterior-compartment disease
Higher rates of arthrofibrosis and wound problems; longer rehabilitation
A combined anterior arthroscopic + open posterior approach is well described for diffuse PVNS to ensure the posterior compartment is fully cleared

Adjuvant Therapy for Diffuse PVNS

Radiosynovectomy (intra-articular radioisotope, e.g. yttrium-90) and external-beam radiotherapy are used to reduce recurrence after subtotal/total synovectomy of diffuse disease
Pexidartinib, a CSF1R inhibitor, is approved for symptomatic diffuse-type TGCT not amenable to surgery (ENLIVEN trial) - hepatotoxicity requires monitoring
Radiosynovectomy is also a mainstay in haemophilic synovitis as a less invasive alternative/adjunct to surgical synovectomy

Evidence Base

Surgery, Surgical Approach and Adjuvant Radiotherapy in Diffuse PVNS

The strongest synthesis is Mollon's individual-patient meta-analysis: across 35 studies and 630 patients, 137 (21.8%) recurred. For diffuse PVNS, recurrence was reduced by open synovectomy (OR 0.47) and most strongly by combined open-and-arthroscopic synovectomy (OR 0.19) versus arthroscopy alone, and by peri-operative radiotherapy (OR 0.31). Surgical approach made no difference for localised disease. This is the evidential basis for the combined anterior-arthroscopic plus open-posterior strategy in diffuse posterior disease.

Long-term natural-history data (Verspoor) show recurrence is a continuing problem: 5-year recurrence-free survival for diffuse PVNS was only 32% (1-year 69%), the knee was affected in 88%, and quality of life was reduced versus population norms - hence the need for structured MRI surveillance, not one-off cure.

Verified Evidence

Combined synovectomy and peri-operative radiotherapy reduce recurrence of diffuse PVNS of the knee

Level III

Mollon B, Lee A, Busse JW, et al. • Bone Joint J (2015)

Clinical Implication: For diffuse PVNS with posterior involvement, prefer a combined anterior-arthroscopic plus open-posterior synovectomy and consider adjuvant radiotherapy to lower recurrence.

Verify on PubMed (PMID 25820897)

Long-term follow-up of primary and recurrent PVNS - recurrence increases with time

Level IV

Verspoor FGM, Zee AAG, Hannink G, et al. • Rheumatology (Oxford) (2014)

Clinical Implication: Counsel patients with diffuse disease about substantial late recurrence and arrange structured long-term MRI surveillance rather than promising cure.

Verify on PubMed (PMID 24917565)

Subtotal synovectomy plus external-beam radiotherapy gives durable control of diffuse knee PVNS

Level IV

de Carvalho LH Jr, Soares LFM, Goncalves MBJ, et al. • Arthroscopy (2012)

Clinical Implication: Where complete synovectomy is not achievable in diffuse disease, subtotal resection combined with radiotherapy can still deliver durable disease control.

Verify on PubMed (PMID 22554472)

ENLIVEN: pexidartinib (CSF1R inhibitor) for advanced tenosynovial giant cell tumour

Level III

Tap WD, Gelderblom H, Palmerini E, et al. • Lancet (2019)

Clinical Implication: Pexidartinib is a systemic option for symptomatic diffuse-type TGCT not amenable to surgery, but mandates baseline and ongoing hepatic monitoring.

Verify on PubMed (PMID 31229240)

Rheumatoid synovectomy - arthroscopic versus open: does approach matter?

Level III

Chalmers PN, Sherman SL, Raphael BS, Su EP • Clin Orthop Relat Res (2011)

Clinical Implication: In the rheumatoid knee, arthroscopic synovectomy is favoured for lower morbidity and equal pain relief, accepting a modestly higher rate of recurrence and radiographic progression than open surgery.

Verify on PubMed (PMID 21213089)

Arthroscopic Recurrence and Function

Aurégan's two-centre series of primary arthroscopic synovectomy (16 nodular, 7 diffuse) reported only 2 recurrences among 21 reviewed patients at mean 7-year follow-up, with significantly improved Tegner-Lysholm scores - confirming arthroscopy can control even diffuse disease in selected hands while preserving function. Capellen's 120-resection single-centre experience, built on meticulous open anterior-and-posterior synovectomy including the popliteal space, achieved an 18% recurrence rate (over 90% recurring within 3 years), reinforcing that completeness of resection - particularly posteriorly - is the key modifiable factor.

Synovial Chondromatosis

A 2025 systematic review (Alamiri) of arthroscopic management found a 22.6% recurrence rate overall, occurring predominantly after loose-body removal alone; recurrence was lower when synovectomy was added, underlining that active synovial metaplasia - not retained loose bodies alone - drives recurrence.

Diagnosis and Classification Essentials

PVNS / Diffuse-type TGCT

Histology: hyperplastic synovium with haemosiderin-laden macrophages, multinucleate giant cells, foam cells and a mononuclear stromal cell population; the underlying biology is driven by CSF1 overexpression recruiting CSF1R-positive cells - the rationale for pexidartinib
Imaging: MRI is the investigation of choice - low signal on T1 and T2 with characteristic blooming on gradient-echo (susceptibility) sequences from haemosiderin; defines disease extent and posterior involvement
Localised vs diffuse is the single most important distinction for planning and prognosis

Synovial Chondromatosis - Milgram Phases

Phase 1: active intrasynovial metaplasia, no loose bodies - synovectomy alone
Phase 2: transitional, active synovium AND loose bodies - synovectomy plus loose-body removal
Phase 3: multiple free loose bodies, quiescent synovium - loose-body removal (with synovectomy of any residual active disease)
Beware rare malignant transformation to chondrosarcoma in long-standing/recurrent disease

Clinical Decision Scenarios

Use these scenarios to practise clinical reasoning and management decisions

CLINICAL SCENARIOStandard

CLINICAL PROMPT

"A 34-year-old presents with a 2-year history of recurrent atraumatic knee effusions, intermittent locking and a brown-stained aspirate. MRI shows diffuse low-signal synovial thickening on T1 and T2 with blooming on gradient-echo sequences, extending into the posterior compartment. How do you interpret this and how would you manage it?"

PRACTICAL APPROACH

The clinical picture - recurrent haemorrhagic effusions, mechanical symptoms, and an MRI showing diffuse synovial thickening with low signal on T1 and T2 and characteristic blooming artefact on gradient-echo - is diagnostic of diffuse pigmented villonodular synovitis, now classified as diffuse-type tenosynovial giant cell tumour. The knee is the most commonly affected joint. The blooming reflects haemosiderin deposition, and the posterior compartment involvement is critical because it predicts both the surgical challenge and the recurrence risk. I would confirm the diagnosis histologically, ideally with synovial biopsy showing haemosiderin-laden macrophages and multinucleate giant cells, and stage the disease with the MRI to map every compartment. Because this is diffuse disease with posterior involvement, the operative aim is a complete total synovectomy. I would not rely on anterior arthroscopy alone - the posterior compartment is the classic site of residual disease and recurrence. My plan would be a combined anterior arthroscopic synovectomy with posteromedial and posterolateral portals, and a low threshold for converting to an open posterior approach to clear the posterior recesses completely while protecting the popliteal neurovascular bundle. Given the high recurrence rate of diffuse disease, reported in the range of 8 to 46 percent, I would plan adjuvant therapy. There is meta-analysis evidence (Mollon, Bone Joint J 2015) that adding radiotherapy to surgical synovectomy lowers the recurrence rate of diffuse PVNS of the knee, and de Carvalho showed durable control with subtotal synovectomy plus radiotherapy. So I would arrange post-operative radiosynovectomy or external-beam radiotherapy, and counsel that if disease recurs and becomes unresectable, systemic pexidartinib, a CSF1R inhibitor proven in the ENLIVEN trial, is an option. I would also set expectations about the real possibility of recurrence and the need for MRI surveillance.

CLINICAL SCENARIOStandard

CLINICAL PROMPT

"A 28-year-old man with severe haemophilia A has recurrent right knee bleeds and a chronically boggy, swollen joint despite factor prophylaxis. He is being considered for knee synovectomy. What are the key considerations and how does this differ from synovectomy in other conditions?"

PRACTICAL APPROACH

In severe haemophilia A the recurrent haemarthroses drive a chronic haemophilic synovitis, and the hypertrophic, hypervascular synovium itself bleeds more easily, perpetuating a vicious bleed-synovitis-bleed cycle that destroys cartilage. The rationale for synovectomy is to break that cycle by removing the diseased synovium, reducing bleed frequency and slowing arthropathy. It is performed earlier in the treatment cascade than arthroplasty and is indicated when bleeds persist despite optimised prophylaxis. The single most important difference from synovectomy in other conditions is that this is as much a haematological procedure as a surgical one. The entire peri-operative plan must be made jointly with haematology. I would screen for factor VIII inhibitors pre-operatively, because an inhibitor fundamentally changes management and may contraindicate surgery in favour of bypassing agents or other strategies. Factor levels must be corrected to around 80 to 100 percent before incision and maintained at therapeutic levels through the inflammatory and rehabilitation period, not just for the day of surgery. Uncorrected coagulopathy is an absolute contraindication. Before committing to surgical synovectomy I would consider radiosynovectomy, an intra-articular radioisotope such as yttrium-90, which is a less invasive and well-established option for haemophilic synovitis and is often tried first. If surgery is chosen, an arthroscopic synovectomy is attractive because it reduces wound morbidity and stiffness, but meticulous haemostasis is paramount because a post-operative haemarthrosis is both a bleed and a stiffness risk. Early supervised motion under continued factor cover is essential, since arthrofibrosis is the major functional complication. I would counsel that the goal is fewer bleeds and slower joint damage rather than cure.

CLINICAL SCENARIOStandard

CLINICAL PROMPT

"Talk me through how you perform an arthroscopic knee synovectomy and ensure it is complete. Where is disease most commonly left behind, and how do you address it safely?"

PRACTICAL APPROACH

I position the patient supine with a thigh tourniquet and a leg holder or side post that lets me flex the knee to ninety degrees and apply valgus and varus stress. I begin with a diagnostic arthroscopy through standard anterolateral viewing and anteromedial working portals, mapping the disease and taking biopsies before resection. A synovectomy is a systematic compartment-by-compartment operation, so I work through every recess rather than just the obvious bulk of disease. I add a superolateral portal for the supra-patellar pouch and outflow, and use a motorised shaver to clear the pouch completely. I then address both the medial and lateral gutters out to the periphery, interchanging viewing and working portals to reach every corner, because peripheral synovium is easily under-resected. Next I clear the intercondylar notch around the cruciates without damaging them, and address the fat pad and ligamentum mucosum, removing any loose bodies if this is synovial chondromatosis. The compartment most commonly left behind, and the classic site of recurrence, is the posterior compartment. I cannot reach it adequately from anterior portals alone, so I flex the knee to ninety degrees, which lets the popliteal neurovascular bundle drop posteriorly and increases my safety margin. I view the posteromedial recess trans-notch using a modified Gillquist approach, transilluminate the skin, and establish a posteromedial portal under direct vision about a centimetre above the joint line behind the medial femoral condyle. I clear the posteromedial recess with the shaver window always facing the joint and never the capsule. For the posterolateral recess I establish a posterolateral portal behind the biceps tendon and lateral collateral ligament, protecting the common peroneal nerve. If the posterior disease is diffuse and cannot be cleared arthroscopically, I have a low threshold to convert to an open posterior approach. Finally I re-inspect every compartment for residual disease, achieve haemostasis, and for diffuse PVNS I plan adjuvant radiotherapy to lower recurrence.